PepsRadar
⌕ Search✧ Ask
Content updated · how dates work
The claim
“Thymosin alpha-1 can cause immune "flare-ups" or make autoimmune conditions worse.”
Verdict: Unproven
No published trial, case series or regulatory document has shown thymosin alpha-1 (TA1) triggering a new autoimmune disease or worsening an existing one in people. In the largest placebo-controlled trial, side effects were as common on placebo as on TA1. But that is not reassurance either: trials generally left out people with active autoimmune disease, so there is almost no data for exactly the people asking.
The worry is a theory, not a documented effect. TA1 activates parts of the immune system, but laboratory work shows it also switches on calming, regulatory signals, so researchers describe it as an immune modulator rather than a simple booster. Randomized trials in sepsis, hepatitis, COVID-19 and cancer did not report autoimmune flares, and the drug label lists only injection-site discomfort and a few rare reactions. The one human report of a severe immune reaction involved a cancer drug that is known to cause such reactions on its own. The real gap is that people with active autoimmune disease have barely been studied.
3:35Video overview · 3:35
Where thymosin alpha-1 is approved, why immune markers are not the same as fewer infections, what the large sepsis and pancreatitis trials found, the hepatitis and COVID-19 evidence, and its FDA and anti-doping status.
Narrated with an AI voice from its profile's sources; education only, no dosing. Read the full page → · Watch on YouTube ↗
Thymosin alpha-1 is a thymus peptide sold as an immune booster. Laboratory studies show it can activate dendritic cells and push immune responses toward the type that fights infections, through toll-like receptor signaling. Its manufacturer's label also says the drug 'appears to work by enhancing the immune system.' From there, it is a short step to the idea that boosting immunity could also stir up autoimmune disease, where the immune system attacks the body.
The same research points the other way too. In a 2006 study, TA1 switched on an enzyme called IDO in dendritic cells, which favors regulatory T cells and the calming signal IL-10. The authors described this as a 'regulatory environment for balance of inflammation and tolerance.' In other words, TA1 appears to adjust immune activity in both directions rather than simply turning it up.
Sources: PubMed 14982877 · PubMed 16741252 · registrasiobat.pom.go.id
The largest trial, TESTS, randomly assigned about 1,100 adults with sepsis to TA1 or placebo. At least one adverse event occurred in 66.4% on TA1 and 67.6% on placebo, and serious adverse events in 26.8% and 29.3%. The authors reported no unexpected serious adverse events related to TA1. An earlier sepsis trial, ETASS, recorded no serious drug-related adverse events.
Trials in chronic hepatitis B reported mostly mild side effects such as injection-site discomfort. The 'flare' that does appear on the label is a different thing: during hepatitis B treatment, liver enzymes can temporarily rise as the immune system attacks the virus, which the label calls a flare. That is a liver-enzyme rise in hepatitis treatment, not an autoimmune flare. In a phase 2 study of lung-cancer patients receiving radiation, moderate or worse radiation pneumonitis (lung inflammation) was less common with TA1 than in matched patients who did not get it.
Sources: PubMed 39814420 · PubMed 23327199 · PubMed 15850471 · PubMed 8855175 · PubMed 35870709 · registrasiobat.pom.go.id
A 2026 case report describes a man with nasopharyngeal cancer who developed fever, rash, lung, liver and blood-clotting problems within two days of a TA1 dose given 11 days after sintilimab, a cancer immunotherapy that releases the immune system's brakes. He improved with steroids. But he already had immune-related skin and liver reactions on day 2 of sintilimab, before he received TA1, and drugs of this type cause such reactions on their own. The authors frame it as possible immune overactivation from the combination, and cause and effect cannot be separated.
Other evidence on the combination points the other way. A 2026 retrospective study of lung-cancer patients found no increase in side effects when TA1 was added to immunotherapy, and in mice TA1 prevented colitis caused by a similar immunotherapy drug (the authors hold a pending patent on that use).
Sources: PubMed 41669704 · PubMed 41994384 · PubMed 32817121
We found no registered clinical trial of TA1 in lupus, rheumatoid arthritis, multiple sclerosis or inflammatory bowel disease. In blood cells from people with relapsing multiple sclerosis, TA1 lowered several inflammatory signals and expanded regulatory B cells in the lab. A non-randomized Chinese study in immune thrombocytopenia, an autoimmune platelet disorder, reported better responses when TA1 was added to steroids. These are laboratory or low-quality studies, but they lean toward calming rather than inflaming.
The only direct evidence that TA1 can worsen autoimmunity comes from a 1985 mouse study of autoimmune thyroid disease. TA1 increased the disease in one mouse strain and suppressed it in another, depending on timing. That works in both directions and has not been shown in people.
Sources: clinicaltrials.gov · PubMed 28273784 · PubMed 17637261 · PubMed 3873993
The biggest gap is the group the question is about. TESTS excluded people with acute-phase autoimmune disease, and most trials did not set out to study people with lupus, rheumatoid arthritis or similar conditions, so there is little data either way. We also found no case report of new or relapsing autoimmune disease blamed on TA1, which is a gap in the literature, not proof of safety. FDA adverse-event reports mentioning thymalfasin or Zadaxin did not include any coded as autoimmune disease or a disease flare, but those reports are voluntary, often involve very sick patients on many drugs, and cannot show cause and effect.
The label does give two practical cautions. It treats the drug as contraindicated in people being deliberately immunosuppressed, such as organ transplant recipients, unless the benefits clearly outweigh the risks, and it urges caution when combining it with other drugs that change immune function. Vials sold online as 'research' TA1 are not the approved product, so even these label findings may not apply to them.
Sources: PubMed 39814420 · registrasiobat.pom.go.id · open.fda.gov
Thymosin alpha-1 profile → · Thymosin alpha-1 risks & interactions →
These are original summaries of published research, written with AI assistance from the cited studies. Each reference was matched to its PubMed record by title, year and journal; the summaries themselves have not been independently checked line by line against the full papers, so errors are possible (corrections). They are not medical advice and have not been reviewed by a clinician. All claim checks · Editorial standards
See something wrong on this page? Report a mistake · Corrections